Effects of Lycium Barbarum Supplements on the Progression of Senile Cataract in Hong Kong Chinese Population

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01142960

Enrollment

238

Registered

2010-06-14

Start date

2009-11-30

Completion date

2012-06-30

Last updated

2016-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lens Opacity

Brief summary

With the rapid growing aging population, age-related eye diseases including cataract are becoming more prevalent. The demand for cataract surgery and post-surgical care posed enormous financial burdens to the government. Lycium barbarum contains lutein and zeaxanthin which can filter the phototoxic blue light and neutralize the reactive oxygen species, thus provide a protective effect against cataract formation. This study aims to determine the effects of Lycium barbarum Supplements on the progression of senile cataract in Hong Kong Chinese elderly.

Detailed description

Please note that a manuscript for this study is being prepared. Detailed description will be provided after we come up with the final draft.

Interventions

DIETARY_SUPPLEMENTStarch

1350mg/day

DIETARY_SUPPLEMENTLycium Barbarum

1350mg/day

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

60 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* Unlikely to have cataract surgery within 3 years * Presence of mild to moderate cataract in one or both eyes, graded by Lens Opacities Classification System III (LOCSIII). * logMAR acuity equivalent to Snellen acuity of 20/63 or better * no previous history and clinical signs of glaucoma by determining intraocular pressure using applanation Tonometry (no more than 22mmHg) * no ocular anomalies: amblyopia, binocular anomalies, ocular trauma * no history of eye surgery, laser treatment, iritis, retinal crystalline deposits, macular degeneration, or optic nerve diseases * no extended use of systemic or ocular corticosteroid drugs * no concurrent participation of other systemic or ocular drug intervention study

Exclusion criteria

* diabetes mellitus * renal failure * fat malabsorption syndrome * intestinal surgery history * chronic diarrhea * alcoholism * use of anticoagulants * regular use of nutritional supplements such as multi-vitamin, mineral and other antioxidant supplements (including Omega-3)

Design outcomes

Primary

Measure	Time frame
Lens Opacity Classification System III (LOCSIII)	3 years

Secondary

Measure	Time frame
Visual Acuity	3 years

Countries

Hong Kong

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026